Genomic and Epigenomic Biomarkers of Toxicology and Disease. Группа авторов
Читать онлайн книгу.
the intracellular small RNA content (~55% of the reads), miRNAs were only the fourth most populated of the EV-derived small RNAs, at around 10% of the total reads. Later studies have both supported and contradicted these findings. For example, Sork et al. (2018) also described different patterns of intracellular small, ribosomal, and other RNAs versus those found in EVs. Of the total reads, small RNAs were a minority; they were noted in the five cell cultures assessed, ranging from ~ 2% to ~ 40% of the reads. However, 58%–83% of the small RNA EV reads were attributed to miRNAs, many of these reflecting those found in the parent cell, with some notable exceptions such as miR-451a. The disagreements between different studies could be due to cell types, methods, and the analyses used. Overall, from a biomarker perspective, the content of these EVs reflects the cellular state and can be specific to a cell type by partially reflecting the transcriptome (Sork et al. 2018; Srinivasan et al. 2019); yet the EVs differ in intracellular RNA content from the source cell (Guduric-Fuchs et al. 2012; Zhang et al. 2010). Therefore packaging these EVs is not merely representative of the RNA cellular milieu; it is rather an active process that may be influenced by cellular responses to stressors.
Many recent studies have focused on determining mechanisms that are involved in EV formation and RNA packaging. The initial formation varies for the different types of EVs. For example, intraluminal vesicles form through the invagination of endosomes known as multivesicular bodies (MVBs), which are then guided by cytoskeletal components and degraded by giant intracellular lysosomes or released into the extracellular space after fusion with the plasma membrane (see reviews in Janas et al. 2015 and O’Brien et al. 2020). Other EVs, such as microvesicles, larger oncosomes, and apoptotic bodies, form directly from the plasma membrane itself. During these processes, RNAs are selectively packaged by the vesiculation machinery through different interactions. These vesicles are enriched with cholesterol, sphingomyelin, glycosphingolipids, and phosphatidylcholine comprised of saturated fatty acids when they are derived from raft-like regions of the MVBs and the plasma membrane. Ceramides, which preferentially locate on the outside rafts of MVBs, are thought to associate with ribonucleoprotein (RNP) complexes and may help selectively package RNA into EVs (Kosaka et al. 2013). Both RNA sequence and RNA secondary structure can mediate this selection (Janas et al. 2006). The sumoylated heterogenous nuclear RNP (specifically, hnRNPA2B1) can recognize the GGAG motif in miRNAs (e.g., miR-198 and -601) and subsequently transfer into exosomes (Villarroya-Beltri et al. 2013) without itself being packaged (Zhou et al. 2020). Sumoylated hnRNPA1 may work in a similar fashion (Li et al. 2004). Also, the synaptotagmin-binding cytoplasmic RNA-interacting protein (SYNCRIP) mediated the sorting of miRNAs bearing the GGCU motif in hepatocyte cell culture (Santangelo et al. 2016). These seed sequences, also termed “EXO-motifs,” are located in the 3ʹ sites of miRNAs (Janas et al. 2006), whereas the sites that mediate mRNA targeting (and primary function) are located in the 5ʹ end. This suggests that the loading of miRNAs into vesicles could occur even if there were very different mRNA targeting functions. It has also been noted in B cells that the post-transcriptional addition of uracil at the 3ʹ end of the miRNA sequence preferentially sorts into exosomes, whereas adenylated miRNAs remain cell-bound (Koppers-Lalic et al. 2014). Other RNA-binding proteins implicated in preferential RNA loading include AGO2 (McKenzie et al. 2016), annexin A2 (Hagiwara et al. 2015), major vault protein (Statello et al. 2018), YBX1 (Kossinova et al. 2017; Shurtleff et al. 2016; Yanshina et al. 2018), lupus La protein (Temoche-Diaz et al. 2019), and Arc1 (Ashley et al. 2018) (see review in O’Brien et al. 2020).
Biological Interpretations Due to Mechanisms of Release
The difference between a “leakage” miRNA biomarker and one that is non-randomly packaged into an EV as a putative communication signal, is an important distinction for development of miRNA biomarkers that are indicative of health effects. For example, mammalian miR-122 has been heavily investigated as a leakage biomarker for liver toxicity, in the context of both non-clinical and clinical species. miR-122 accounts for approximately 72% of the total liver miRNAs in mice (Lagos-Quintana et al. 2002) and is highly specific for human, mouse, and rat livers (Landgraf et al. 2007; Smith et al. 2016). In a landmark study by Wang et al. (2009), mice were treated with hepatotoxic levels of acetominophen (APAP) and miRNA microarrays were used to measure difference in the plasma. Forty-four miRNAs were significantly altered, miR-122 showing a 470-fold increase twenty-four hours after APAP overdose, and these alterations could be observed as soon as one hour after exposure. This APAP overdose or acute liver injury-associated miR-122 release was later confirmed in human patients (Starkey Lewis et al. 2011). The observation that decreased liver-based miRNAs with APAP hepatotoxicity correlated with increases in serum plasma suggested that these miRNAs were released as packaged contents or leaked during hepatocyte necrosis; the leakage theory was supported by Arroyo et al. (2011), who demonstrated that miR-122 was primarily associated with a RNP complex (Ago2) and was not membrane-bound as in exosomes. However, later studies provided clues that the mechanism of miR-122 release from liver was context-dependent, that is, dependent on factors such as the condition of the liver, the timing of the injury or perturbation, the half-life of a miRNA, and baseline variability. Subtoxic exposures in vitro result primarily in hepatocyte-derived release of exosome-bound miR-122 (Holman et al. 2016; Mosedale et al. 2018), and alcoholic and inflammatory liver disease was associated with exosome-bound miR-122—as opposed to drug-induced injury, which was found in the protein-bound fraction of plasma (Bala et al. 2012). Further, the protection of miRNA from RNases present in biofluids may preferentially enrich exosome and protein-bound miRNAs (Arroyo et al. 2011; Koberle et al. 2013; Li et al. 2012; Turchinovich et al. 2011).
Therefore the decision whether to quantify miRNA biomarkers from unfractionated samples or from isolated EVs may depend on context and on intended use. Additionally, questions remain as to which one is more reliable in biomarker measurements; and some reports suggest that this may depend on the specific human disease. A disease-specific alteration in exosome release and clearance, or the administration of therapeutics that alter the volume of blood, can skew the yield (Buschmann et al. 2018; Hanna et al. 2019). The isolation of miRNAs from unfractionated biofluid samples should capture both miRNAs that originate from passive leakage into the sampled matrix and miRNAs that come from actively released membrane-bound vesicles lysed through the isolation procedure. This isolation avoids major drawbacks of vesicle purification, which lowers RNA yield and integrity and can result is greater experimental variability. Another challenge is that, depending on the method used, different populations of EVs are isolated; and this produces only partially overlapping RNA profiles (Buschmann et al. 2018). Recently, a comprehensive analysis of published results compared the utility of miRNAs isolated from EVs to the utitliy of those isolated from unfractionated whole serum or plasma for specific biomarker use (Nik Mohamed Kamal and Shahidan 2019). Twenty of the thirty-two studies cited suggested that EV-derived miRNAs may be preferable for the intended use examined. A commonly reported reason was the potential for increased stability that might be derived from being encapsulated in a vesicle. But it is also important to note that these intended uses varied, and included both in vitro and in vivo biomarker development for heart failure, chronic pain, septic shock, non-alcoholic fatty liver disease, immunization, and many types of cancer. So, while a slight majority of studies recommended vesicle fraction miRNA for biomarker measurement, specific research needs to be performed to provide the appropriate conditions and context of use.
MicroRNAs as Bioindicators of Toxicity and Disease
Much miRNA biomarker research has been focused on the early detection of drug-induced liver injury (DILI), a major roadblock in drug development. Alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and total bilirubin are the currently approved DILI biomarkers in clinical practice (Robles-Diaz et al. 2016). These biomarkers are not specific to hepatotoxicity, as they increase in almost all abnormal liver conditions. Furthermore, they lack sensitivity, as they appear once liver damage has developed, and consequently have limited use for predicting potential liver injury at an early stage. For this reason, circulating miRNAs are being investigated for the monitoring of drug-induced tissue injury (tissue degeneration and necrosis) in cases where highly abundant tissue-specific miRNAs are passively released after cell injury. In incidences of DILI, studies have demonstrated that miR-122 presence in blood correlates tightly with pathological indications and clinical chemistries (i.e., ALT, AST) of liver